Company: NCEL
Filing Date: 2025-04-24
Form Type: 6-K
Source: 0001213900-25-035051
Chunk: 0

Company: NewcelX Ltd.
Filing Date: 2025-04-24
Form: 6-K
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of April 2025 (Report No. 2)

Commission file number: 001-39957

NLS PHARMACEUTICS LTD.

(Translation of registrant’s name into English)

The Circle 6

8058 Zurich, Switzerland

(Address of principal executive offices)</div>

Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.

<div align='center'>Form 20-F ☒ Form
40-F ☐

CONTENTS</div>

Resignation of Director

On April 18, 2025, Audrey Greenberg, a member of the Board of Directors
of NLS Pharmaceutics Ltd., or the Company, notified the Company of her intention to resign from the Company’s Board of Directors,
effective April 18, 2025. The resignation of Audrey Greenberg was not based on any material disagreement with the Company on any matter
relating to its operations, policies or practice. The resignation is consistent with the Company’s ongoing efforts to reduce cash
burn and aligns with the anticipated post-merger composition of the board of directors, pursuant to which all current directors, with
one exception, are expected to step down.

This
Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Company’s Registration Statements on Form F-3
(File Nos. 333-284696, 333-284811, 333-282788, 333-262489, 333-268690 and 333-269220),
filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent
not superseded by documents or reports subsequently filed or furnished.

<div align='center'>1

SIGNATURES</div>

Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.

| Date: April 24, 2025 | NLS Pharmaceutics Ltd. 
 By:                    |